Abstract

Serotype-specific antibody concentration and opsonophagocytic activity (OPA) were evaluated after 3 doses of pneumococcal conjugate vaccine. Groups included human immunodeficiency virus (HIV)–positive infants with CD4+ cell percentages ≥25% who initiated immediate antiretroviral treatment (the HIV+/ART+ group) or whose antiretroviral treatment was deferred until clinically or immunologically indicated (the HIV+/ART− group). Immune responses were also evaluated in HIV-noninfected infants born to HIV-seronegative (M−/I−) or HIV-positive mothers (M+/I–). Antibody concentrations were similar between HIV+/ART+ and HIV+/ ART− infants. However, antibody concentrations were lower in M−/I− infants than in M+/I− infants. Nevertheless, M−/ I− infants had superior OPA responses, compared with those in HIV+/ART+ infants, who in turn had better OPA responses, compared with those in HIV+/ART− infants.

You do not currently have access to this article.